Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling

The present studies sought to further understand how the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib interact to kill tumor cells. Sorafenib activated SRC, and via SRC the drug combination activated ERK1/2. Expression of dominant negative SRC or dominant negative MEK1 abolished d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bareford, M. Danielle, Hamed, Hossein A., Allegood, Jeremy, Cruickshanks, Nichola, Poklepovic, Andrew, Park, Margaret A., Ogretmen, Besim, Spiegel, Sarah, Grant, Steven, Dent, Paul
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2012
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3679099/
https://ncbi.nlm.nih.gov/pubmed/22673740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.20562
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars